Clinical usefulness of testing for UDP glucuronosyltransferase 1 family, polypeptide A1 polymorphism prior to the inititation of irinotecan-based chemotherapy

Harada,Taishi; Saito,Haruhiro; Karino,Fumi; Isaka,Tetsuya; Murakami,Shuji; Kondo,Tetsuro; Oshita,Fumihiro; Miyagi,Yohei; Yamada,Kouzo

doi:10.3892/mco.2014.308

Clinical usefulness of testing for UDP glucuronosyltransferase 1 family, polypeptide A1 polymorphism prior to the inititation of irinotecan-based chemotherapy

Authors:
- Taishi Harada
- Haruhiro Saito
- Fumi Karino
- Tetsuya Isaka
- Shuji Murakami
- Tetsuro Kondo
- Fumihiro Oshita
- Yohei Miyagi
- Kouzo Yamada
View Affiliations

Affiliations: Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Kanagawa 241-0815, Japan, Research Institute, Kanagawa Cancer Center, Yokohama, Kanagawa 241-0815, Japan
Published online on: June 6, 2014 https://doi.org/10.3892/mco.2014.308
Pages: 737-743

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

An association between UDP glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) polymorphisms and irinotecan-induced neutropenia has been previously reported. In this study, we assessed the clinical usefulness of testing for UGT1A1 polymorphisms prior to the initiation of irinotecan‑based chemotherapy, as this remains a controversial subject. A total of 136 lung cancer patients who were treated with a combination of nedaplatin and irinotecan as initial chemotherapy were assessed. Following exclusion of patients exhibiting low UGT1A1 enzyme activity, 70 patients were treated after UGT1A1 polymorphism testing (test group) and 66 patients were treated without UGT1A1 polymorphism testing (non-test group). We retrospectively analyzed and compared the adverse events between the test and the non‑test groups and observed no reduction in hematological or non‑hematological toxicities in the test group compared to that in the non‑test group. Of the 9 patients with grade 4 or 5 non‑hematological toxicity, 6 patients had febrile neutropenia (FN). All the patients with FN were aged >70 years. The incidence of adverse events was significantly higher among patients aged >70 years compared to that among younger patients. In conclusion, in patients treated with nedaplatin and irinotecan combination chemotherapy, UGT1A1 polymorphism testing prior to the initiation of chemotherapy did not reduce the incidence of adverse events. Therefore, UGT1A1 polymorphism testing alone may not be sufficient to predict the occurrence of severe adverse events and it may be more important to effectively manage adverse events, particularly in elderly patients.

View Figures

View References

1	Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL and Ratain MJ: Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest. 101:847–854. 1998. View Article : Google Scholar
2	Lokiec F, Canal P, Gay C, Chatelut E, Armand JP, Roché H, Bugat R, Gonçalvès E and Mathieu-Boué A: Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine. Cancer Chemother Pharmacol. 36:79–82. 1995. View Article : Google Scholar : PubMed/NCBI
3	Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, Kaniwa N, Sawada J, Hamaguchi T, Yamamoto N, Shirao K, Yamada Y, Ohmatsu H, Kubota K, Yoshida T, Ohtsu A and Saijo N: Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1^6 and ^28. Parmacogenet Genomics. 17:497–504. 2007. View Article : Google Scholar : PubMed/NCBI
4	Iyer L, Das S, Janisch L, Wen M, Ramírez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL and Ratain MJ: UGT1A1^*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2:43–47. 2002.
5	Sai K, Saeki M, Saito Y, Ozawa S, Katori N, Jinno H, Hasegawa R, Kaniwa N, Sawada J, Komamura K, Ueno K, Kamakura S, Kitakaze M, Kitamura Y, Kamatani N, Minami H, Ohtsu A, Shirao K, Yoshida T and Saijo N: UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther. 75:501–515. 2004. View Article : Google Scholar
6	Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, Jang IJ, Lee DH and Lee JS: Comprehensive analysis of UGT1A1 polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol. 24:2237–2244. 2006. View Article : Google Scholar : PubMed/NCBI
7	Glimelius B, Garmo H, Berglund A, Fredriksson LA, Berglund M, Kohnke H, Byström P, Sørbye H and Wadelius M: Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J. 11:61–71. 2011. View Article : Google Scholar : PubMed/NCBI
8	Shulman K, Cohen I, Barnett-Griness O, Kuten A, Gruber SB, Lejbkowicz F and Rennert G: Clinical implications of UGT1A1^*28 genotype testing in colorectal cancer patients. Cancer. 117:3156–3162. 2011.PubMed/NCBI
9	Okuyama Y, Hazama S, Nozawa H, Kobayashi M, Takahashi K, Fujikawa K, Kato T, Nagata N, Kimura H, Oba K, Sakamoto J and Mishima H: Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1^28/^6 polymorphisms. Jpn J Clin Oncol. 41:477–482. 2011. View Article : Google Scholar : PubMed/NCBI
10	Yamamoto N, Takahashi T, Kunikane H, Masuda N, Eguchi K, Shibuya M, Takeda Y, Isobe H, Ogura T, Yokoyama A and Watanabe K: Phase I/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan. Clinical Pharmacol Ther. 85:149–154. 2009. View Article : Google Scholar : PubMed/NCBI
11	Akiyama Y, Fujita K, Nagashima F, Yamamoto W, Endo H, Sunakawa Y, Yamashita K, Ishida H, Mizuno K, Araki K, Ichikawa W, Miya T, Narabayashi M, Kawara K, Sugiyama M, Hirose T, Ando Y and Sasaki Y: Genetic testing for UGT1A1^28 and ^6 in Japanese patients who receive irinotecan chemotherapy. Ann Oncol. 19:2089–2094. 2008.PubMed/NCBI
12	Oshita F, Saito H and Yamada K: Feasible combination chemotherapy with nedaplatin and irinotecan for patients with non-small cell lung cancer and multiple risk factors. J Exp Ther Oncol. 6:251–256. 2007.PubMed/NCBI
13	Oshita F, Yamada K, Kato Y, Ikehara M, Noda K, Tanaka G, Nomura I, Suzuki R and Saito H: Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 52:73–78. 2003. View Article : Google Scholar : PubMed/NCBI
14	Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S and Saijo N; Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 346:85–91. 2002. View Article : Google Scholar : PubMed/NCBI
15	Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y and Fukuoka M: Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol. 18:317–323. 2007. View Article : Google Scholar : PubMed/NCBI
16	Kanzawa F, Koizumi F, Koh Y, Nakamura T, Tatsumi Y, Fukumoto H, Saijo N, Yoshioka T and Nishio K: In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction. Clin Cancer Res. 7:202–209. 2001.
17	Matsukuma S, Saito H, Yamada K, Okamoto N, Ishikawa T, Yoshihara M, Koizume S, Sakuma Y and Miyagi Y: Simple and precise detection of UGT1A1 polymorphisms with a modified loop-hybrid mobility shift assay using Cy5-labeled loop probes. Clin Chim Acta. 412:1668–1672. 2011. View Article : Google Scholar : PubMed/NCBI
18	Sobin LH, Gospodarowicz MK and Wittekind C: TNM Classification of Malignant Tumors. 7th edition. Wiley-Blackwell; NY: 2009
19	Satoh T, Ura T, Yamada Y, Yamazaki K, Tsujinaka T, Munakata M, Nishina T, Okamura S, Esaki T, Sasaki Y, Koizumi W, Kakeji Y, Ishizuka N, Hyodo I and Sakata Y: Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1^28 and/or UGT1A1^6 polymorphisms. Cancer Sci. 102:1868–1873. 2011. View Article : Google Scholar : PubMed/NCBI
20	Marcuello E, Páez D, Paré L, Salazar J, Sebio A, del Rio E and Baiget M: A genotype-directed phase I–IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. Br J Cancer. 105:53–57. 2011.
21	Hoskins JM, Goldberg RM, Qu P, Ibrahim JG and McLeod HL: UGT1A1^*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst. 99:1290–1295. 2007.PubMed/NCBI
22	Hu ZY, Yu Q, Pei Q and Guo C: Dose-dependent association between UGT1A1^*28 genotype and irinotecan-induced neutropenia: low doses also increase risk. Clin Cancer Res. 16:3832–3842. 2010.PubMed/NCBI
23	Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K and Talcott J: The multinational association for supportive care in cancer risk index. A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 18:3038–3051. 2000.
24	Klastersky J, Paesmans M, Georgala A, Muanza F, Plehiers B, Dubreucq L, Lalami Y, Aoun M and Barette M: Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol. 24:4129–4134. 2006. View Article : Google Scholar : PubMed/NCBI
25	Hu ZY, Yu Q and Zhao YS: Dose-dependent association between UGT1A1^*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis. Eur J Cancer. 46:1856–1865. 2010. View Article : Google Scholar : PubMed/NCBI
26	Di Martino MT, Arbitrio M, Leone E, Guzzi PH, Rotundo MS, Ciliberto D, Tomaino V, Fabiani F, Talarico D, Sperlongano P, Doldo P, Cannataro M, Caraglia M, Tassone P and Tagliaferri P: Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study. Cancer Biol Ther. 12:780–787. 2011.
27	Bleiberg H and Cvitkovic E: Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective. Eur J Cancer. 32A(Suppl 3): S18–S23. 1996. View Article : Google Scholar : PubMed/NCBI
28	Merrouche Y, Extra JM, Abigerges D, Bugat R, Catimel G, Suc E, Marty M, Hérait P, Mahjoubi M and Armand JP: High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: A feasibility study. J Clin Oncol. 15:1080–1086. 1997.
29	Takeda Y, Kobayashi K, Akiyama Y, Soma T, Handa S, Kudoh S and Kudo K: Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients. Int J Cancer. 92:269–275. 2001. View Article : Google Scholar : PubMed/NCBI